ClinicalTrials.gg
Active, not recruitingNCT03395197TALAPRO-2Updated Nov 5, 2026Results posted

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

A Phase 3 interventional study of Talazoparib with enzalutamide and Placebo with enzalutamide in mCRPC, sponsored by Pfizer. Active, not recruiting at 370 sites in 26 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,054
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Read the detailed description

Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC.

02

Conditions studied

  • mCRPC

Keywords

  • mCRPC (metastatic castration-resistant prostate cancer)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

or cytologically confirmed adenocarcinoma of the prostate without small cell or signet cell features

Asymptomatic or mildly symptomatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be \< 4).

For enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status

Consent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1).

Surgically or medically castrated, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening.

Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan.

Progressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:

  • Prostate specific antigen (PSA) progression defined by a minimum of 2 rising PSA values from 3 consecutive assessments with an interval of at least 7 days between assessments..
  • Soft tissue disease progression as defined by 1.1.
  • Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan.

Ongoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory.

(ECOG) performance status ≤ 1.

≥ 12 months as assessed by the investigator.

Able to swallow the study drug and have no known intolerance to study drugs or .

Must agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of to use an additional highly effective form of from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential.

Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.

Evidence of a personally signed and dated document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study.

Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

Any prior systemic cancer treatment initiated in in the non CRPC and mCRPC disease state.

Patients whose only evidence of metastasis is adenopathy below the aortic bifurcation.

Prior treatment with second-generation androgen receptor inhibitors (enzalutamide, apalutamide, and darolutamide), a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer.

Prior treatment with platinum-based chemotherapy within 6 months (from the last dose) prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy within 6 months (from the last dose).

Treatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T, or radionuclide therapy received in the castration-sensitive prostate cancer is NOT exclusionary if discontinued in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Treatment with any agent within 4 weeks before Day 1 (Part 1) or randomization (Part 2).

Prior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Current use of potent P-gp inhibitors within 7 days prior to Day 1 (Part 1) or randomization (Part 2).

Major surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2), or palliative localized radiation therapy within 3 weeks before randomization (Part 2).

cardiovascular disease

Significant renal dysfunction as defined by any of the following laboratory abnormalities:

  • Renal: \< 30 mL/min/1.73 m2 by the MDRD equation (available via www.mdrd.com).

Patients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening.

Significant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:

  • Total serum >1.5 times the (ULN) (>3 × ULN for patients with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation).
  • (AST) or alanine aminotransferase (ALT) >2.5 times ULN (>5 × ULN if liver function abnormalities are due to hepatic metastasis).
  • Albumin \<2.8 g/dL

\< 1500/µL, \< 100,000/µL, or \< 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).

Known or suspected or active .

Symptomatic or impending spinal cord compression or cauda equina syndrome.

Any history of myelodysplastic syndrome, acute myeloid leukemia, or prior except any of the following:

  • Carcinoma in situ or non melanoma skin cancer
  • Any prior malignancies ≥3 years before randomization with no subsequent evidence of recurrence or progression regardless of the stage.
  • Stage 0 or Stage 1 cancer \<3 years before randomization that has a remote probability of recurrence or progression in the opinion of the investigator

Gastrointestinal disorder affecting absorption.

Fertile male subjects who are unwilling or unable to use highly effective methods of for the duration of the study and for 4 months after the last dose of investigational product.

Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.

Other acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or within 12 months of randomization (Part 2).

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,054 participants (actual)

Study arms

  • Experimental
    Combination arm

    Talazoparib plus enzalutamide

    Drug: Talazoparib with enzalutamide

  • Active comparator
    Monotherapy arm

    Ezalutamide plus placebo

    Drug: Placebo with enzalutamide

Interventions

  • DrugTalazoparib with enzalutamide

    Drug pages: Talazoparib · Enzalutamide

    Talazoparib 0.5 mg/day plus enzalutamide 160mg/day

  • DrugPlacebo with enzalutamide

    Placebo plus enzalutamide 160 mg/day

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1

    An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per Common Terminology Criteria for Adverse Events (CTCAE) version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.

    Time frame: Post dose on Day 1 up to Day 66 in Part 1

  2. Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1

    An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. Medical Dictionary for Regulatory Activities (MedDRA) v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.

    Time frame: Post dose on Day 1 up to Day 66 in Part 1

  3. Number of Participants With All-Causality TEAEs During the Overall Period of Part 1

    An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.

    Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

  4. Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1

    An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. Treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.

    Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

  5. Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1

    An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.

    Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

  6. Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1

    An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are newly occurring AEs or those worsening after first dose. Treatment-related AE was any AE attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with incidence in \>=10% of participants are reported. Results as of 16 Aug 2022 are reported.

    Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

  7. Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1

    rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by computed tomography (CT) of chest and CT or magnetic resonance imaging (MRI) of abdomen and pelvis. Progression is defined using RECIST 1.1 as a \>=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Results as of 16 Aug 2022 are reported for this outcome measure.

    Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 42 months)

  8. BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2

    rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by CT of chest and CT or MRI of abdomen and pelvis. Results as of 03 Oct 2022 are reported for this outcome measure.

    Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 38 months)

07

Results

Posted Jan 17, 2024

Participant flow

As of the data cutoff for the primary completion date (PCD) on 16 Aug 2022 for Part 1 and Part 2 Cohort 1 and on 03 Oct 2022 for Part 2 Cohort 2, for overall study, 2896 participants were screened for participation in the C3441021 study. As of 03 Oct 2022, a total of 1054 participants were enrolled in this study.

Study Recruitment
Participant flow — Study Recruitment
MilestonePart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient)Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient)
Started136402403115115
Completed136402403115115
Not completed000000
Analysis for Part 1 and Part 2 Cohort 1
Participant flow — Analysis for Part 1 and Part 2 Cohort 1
MilestonePart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient)Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient)
Started13640240300
Completed000000
Not completed13640240300
Withdrew: Lost to follow-up000100
Withdrew: Death0081000
Withdrew: No longer meets eligibility ceriteria001000
Withdrew: No longer clinically benefiting00142100
Withdrew: Not treated with talazoparib005300
Withdrew: Adverse event93694300
Withdrew: Progressive disease117612400
Withdrew: Withdrawal by subject01293000
Withdrew: Global deterioration of health status10444600
Withdrew: Other114500
Withdrew: Ongoing1015212000
Analysis for DDR-Deficient Participants
Participant flow — Analysis for DDR-Deficient Participants
MilestonePart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient)Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient)
Started0000200199
Completed000000
Not completed0000200199
Withdrew: Death000014
Withdrew: No longer clinically benefiting000058
Withdrew: Not treated with talazoparib000030
Withdrew: Adverse event00001911
Withdrew: Progressive disease00003960
Withdrew: Withdrawal by subject00001113
Withdrew: Global deterioration of health status00002440
Withdrew: Other000033
Withdrew: Ongoing00009560

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1

An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per Common Terminology Criteria for Adverse Events (CTCAE) version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.

Time frame:
Post dose on Day 1 up to Day 66 in Part 1
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1
ParticipantsPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+Enzalutamide
Participants with TEAEs136
Participants with medication error TEAE00
Participants with serious TEAE10
Participants with Maximum Grade 3 or 4 TEAE81
Participants with Maximum Grade 5 TEAE00
PrimaryNumber of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. Medical Dictionary for Regulatory Activities (MedDRA) v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.

Time frame:
Post dose on Day 1 up to Day 66 in Part 1
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1
ParticipantsPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+Enzalutamide
Grade 2 Anemia20
Grade 3 Anemia61
Grade 1 Neutropenia10
Grade 2 Neutropenia10
Grade 3 Neutropenia40
Grade 2 Leukopenia10
Grade 3 Leukopenia30
Grade 3 Thrombocytopenia20
PrimaryNumber of Participants With All-Causality TEAEs During the Overall Period of Part 1

An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.

Time frame:
Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality TEAEs During the Overall Period of Part 1
ParticipantsPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+Enzalutamide
Participants with TEAEs136
Participants with medication error TEAE00
Participants with serious TEAE63
Participants with Maximum Grade 3 or 4 TEAE116
Participants with Maximum Grade 5 TEAE10
PrimaryNumber of Participants With Treatment-Related TEAEs During the Overall Period of Part 1

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. Treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.

Time frame:
Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1
ParticipantsPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+Enzalutamide
Participants with TEAEs136
Participants with medication error TEAE00
Participants with serious TEAE21
Participants with Maximum Grade 3 or 4 TEAE104
Participants with Maximum Grade 5 TEAE10
PrimaryNumber of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.

Time frame:
Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1
ParticipantsPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+Enzalutamide
Grade 3 Anemia103
Grade 1 Neutropenia10
Grade 2 Neutropenia10
Grade 3 Neutropenia60
Grade 2 Leukopenia10
Grade 3 Leukopenia50
Grade 3 Thrombocytopenia30
Grade 4 Anemia01
Grade 2 Lymphopenia10
Grade 3 Lymphopenia20
PrimaryNumber of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are newly occurring AEs or those worsening after first dose. Treatment-related AE was any AE attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with incidence in \>=10% of participants are reported. Results as of 16 Aug 2022 are reported.

Time frame:
Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1
ParticipantsPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+Enzalutamide
Grade 3 Anemia103
Grade 1 Neutropenia10
Grade 2 Neutropenia10
Grade 3 Neutropenia60
Grade 2 Leukopenia20
Grade 3 Leukopenia40
Grade 3 Thrombocytopenia30
Grade 4 Anemia01
Grade 2 Lymphopenia10
Grade 3 Lymphopenia20
PrimaryBlinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1

rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by computed tomography (CT) of chest and CT or magnetic resonance imaging (MRI) of abdomen and pelvis. Progression is defined using RECIST 1.1 as a \>=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Results as of 16 Aug 2022 are reported for this outcome measure.

Time frame:
From the start of treatment to the time of first documented progression, or death (maximum up to 42 months)
Reported as:
Median · Months
Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1
MonthsPart 2 Cohort 1: Talazoparib+EnzalutamidePart 2 Cohort 1: Placebo+Enzalutamide
Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1NA (27.5 to NA)21.9 (16.6 to 25.1)
Statistical analysis
  • Part 2 Cohort 1: Talazoparib+Enzalutamide vs Part 2 Cohort 1: Placebo+Enzalutamide · Log Rank · p = <0.0001 (1-sided) · Hazard ratio (hr): 0.627 · 95% CI 0.506 to 0.777Hazard ratio was based on Cox proportional hazards model; under proportional hazards, if hazard ratio \< 1, it indicates reduction in hazard rate in favor of Talazoparib+Enzalutamide compared to Placebo+Enzalutamide.
PrimaryBICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2

rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by CT of chest and CT or MRI of abdomen and pelvis. Results as of 03 Oct 2022 are reported for this outcome measure.

Time frame:
From the start of treatment to the time of first documented progression, or death (maximum up to 38 months)
Reported as:
Median · Months
BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2
MonthsPart 2 Participants With DDR Deficiencies: Talazoparib+EnzalutamidePart 2 Participants With DDR Deficiencies: Placebo+Enzalutamide
BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2NA (21.9 to NA)13.8 (11.0 to 16.7)
Statistical analysis
  • Part 2 Participants With DDR Deficiencies: Talazoparib+Enzalutamide vs Part 2 Participants With DDR Deficiencies: Placebo+Enzalutamide · Log Rank · p = <0.0001 (1-sided) · Hazard ratio (hr): 0.447 · 95% CI 0.328 to 0.610Hazard ratio was based on Cox proportional hazards model; under proportional hazards, hazard ratio \< 1 indicates reduction in hazard rate in favor of Talazoparib+Enzalutamide compared to Placebo+Enzalutamide.

Adverse events

Collected over Post first dose of any study intervention through 28 days after the last dose of study intervention (up to a maximum of 236 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Talazoparib 1 mg QD+Enzalutamide5/13 (38.5%)6/13 (46.2%)13/13 (100%)
Part 1: Talazoparib 0.5 mg QD+Enzalutamide2/6 (33.3%)3/6 (50%)6/6 (100%)
Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)123/402 (30.6%)157/398 (39.4%)377/398 (94.7%)
Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)129/403 (32%)107/401 (26.7%)351/401 (87.5%)
Part 2 Participants With DDR Deficiencies: Talazoparib+Enzalutamide43/200 (21.5%)60/198 (30.3%)190/198 (96%)
Part 2 Participants With DDR Deficiencies: Placebo+Enzalutamide53/199 (26.6%)40/199 (20.1%)182/199 (91.5%)
Most frequent serious events
Showing 10 of 230
Most frequent serious events
EventPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Participants With DDR Deficiencies: Talazoparib+EnzalutamidePart 2 Participants With DDR Deficiencies: Placebo+Enzalutamide
AnaemiaBlood and lymphatic system disorders1/131/655/3981/40117/1982/199
CholecystitisHepatobiliary disorders0/131/61/3982/4011/1980/199
HyperglycaemiaMetabolism and nutrition disorders0/131/60/3980/4010/1980/199
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/131/66/3982/4012/1981/199
Aortic thrombosisVascular disorders0/131/60/3980/4010/1980/199
Cardiac failureCardiac disorders1/130/61/3982/4010/1981/199
DiverticulitisInfections and infestations1/130/61/3981/4010/1980/199
Infectious pleural effusionInfections and infestations1/130/60/3980/4010/1980/199
PneumoniaInfections and infestations1/130/64/3981/4011/1981/199
Pneumonia necrotisingInfections and infestations1/130/60/3980/4010/1980/199
Most frequent other events
Showing 10 of 159
Most frequent other events
EventPart 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Participants With DDR Deficiencies: Talazoparib+EnzalutamidePart 2 Participants With DDR Deficiencies: Placebo+Enzalutamide
FatigueGeneral disorders5/135/6134/398118/40166/19853/199
AnaemiaBlood and lymphatic system disorders10/134/6258/39870/401127/19830/199
Neutrophil count decreasedInvestigations8/130/6142/39828/40164/19813/199
NauseaGastrointestinal disorders7/132/681/39850/40140/19834/199
Decreased appetiteMetabolism and nutrition disorders7/133/686/39863/40140/19828/199
DiarrhoeaGastrointestinal disorders3/133/657/39855/40124/19822/199
Influenza like illnessGeneral disorders1/133/65/39810/4012/1984/199
FallInjury, poisoning and procedural complications4/133/668/39858/40124/19824/199
White blood cell count decreasedInvestigations6/130/688/39818/40137/19815/199
VomitingGastrointestinal disorders5/131/628/39822/40115/19810/199

Baseline characteristics

Included all participants who received at least 1 dose of study treatment (talazoparib or enzalutamide) in Part 1, and all participants who were randomized to double-blind study treatment in Part 2 regardless of whether or not treatment was administered.

Age, Customized
Age, Customized(Participants)Part 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient)Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient)Total
<65 years1279942526227
65-<75 years841881755355483
>=75 years401351343734344
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient)Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient)Total
Female0000000
Male1364024031151151054
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Talazoparib 1 mg QD+EnzalutamidePart 1: Talazoparib 0.5 mg QD+EnzalutamidePart 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient)Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient)Total
White1262432558890694
Black or African American001154323
Asian001271201312272
American Indian or Alaska Native1000001
Native Hawaiian or Other Pacific Islander0021104
Not Reported00192181058
Unknown0000101
Multiracial0001001
08

Study locations

370 sites

Showing the first 100 of 370 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yip SM, Laird AD, Agarwal N, Zschabitz S, Fizazi K, Matsubara N, Joung JY, Karsh LI, Carles J, Fay AP, Piulats JM, Fong PCC, Liu G, Albacker LA, Pasquina LW, Chelliserry J, Healy CG, Lin X, Kalac M, Azad AA. Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling. Lancet Oncol. 2026 Oct 28:S1470-2045(26)00355-4. doi: 10.1016/S1470-2045(26)00355-4. Online ahead of print. PubMed 42950862 ↗
  • Yajima S, Yoshida S, Chen W, Fukushima H, Tanaka H, Sato H, Hirakawa A, Masuda H, Fujii Y. Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. Int J Urol. 2026 Jul;33(7):e70582. doi: 10.1111/iju.70582. PubMed 42502892 ↗
  • Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschabitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K. A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer. Future Oncol. 2026 Jun;22(14):1687-1702. doi: 10.1080/14796694.2026.2668552. Epub 2026 Jun 9. PubMed 42261883 ↗
  • Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Ye D, Lin X, Kalac M, Laird AD, Kennedy D, Agarwal N. A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes. Future Oncol. 2026 Jun;22(14):1669-1685. doi: 10.1080/14796694.2026.2661093. Epub 2026 Jun 4. PubMed 42237765 ↗
  • Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschabitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):447-460. doi: 10.1016/S0140-6736(25)00684-1. Epub 2025 Jul 16. PubMed 40683290 ↗
  • Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):461-474. doi: 10.1016/S0140-6736(25)00683-X. Epub 2025 Jul 16. PubMed 40683287 ↗
  • Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschabitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, Agarwal N. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol. 2025 Apr;26(4):481-490. doi: 10.1016/S1470-2045(25)00031-2. PubMed 40179907 ↗
  • Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschabitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol. 2025 Apr;26(4):470-480. doi: 10.1016/S1470-2045(25)00030-0. PubMed 40179906 ↗
  • Matsubara N, Miyake H, Uemura H, Mizokami A, Kikukawa H, Kosaka T, Nishimura K, Nakamura M, Kobayashi K, Komaru A, Mori Y, Toyoizumi S, Hori N, Umeyama Y, Uemura H. Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis. Cancer Med. 2025 Jan;14(1):e70333. doi: 10.1002/cam4.70333. PubMed 39737542 ↗
  • Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschabitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024 Dec;213:115078. doi: 10.1016/j.ejca.2024.115078. Epub 2024 Oct 20. PubMed 39486165 ↗
  • Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. The TALAPRO-3 study design: a plain language summary. Future Oncol. 2024;20(30):2225-2231. doi: 10.1080/14796694.2024.2363131. Epub 2024 Jul 24. PubMed 39451095 ↗
  • Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer. Future Oncol. 2024;20(29):2123-2135. doi: 10.1080/14796694.2024.2362108. Epub 2024 Jul 12. PubMed 38995237 ↗
  • Heiss BL, Chang E, Gao X, Truong T, Brave MH, Bloomquist E, Shah A, Hamed S, Kraft J, Chiu HJ, Ricks TK, Tilley A, Pierce WF, Tang L, Abukhdeir A, Kalavar S, Philip R, Tang S, Pazdur R, Amiri-Kordestani L, Kluetz PG, Suzman DL. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2024 May 20;42(15):1851-1860. doi: 10.1200/JCO.23.02182. Epub 2024 Mar 7. PubMed 38452327 ↗
  • Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. PubMed 38049622 ↗
  • Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4. PubMed 37285865 ↗
  • Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol. 2022 Feb;18(4):425-436. doi: 10.2217/fon-2021-0811. Epub 2022 Jan 26. PubMed 35080190 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Oct 2022, 57 months.

Results were first posted in Jan 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2017
First posted
Jan 10, 2018
StartActual
Dec 18, 2017
Primary completionActual
Oct 3, 2022
CompletionEst.
Jun 30, 2027
Results first posted
Jan 17, 2024
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42950862 ↗
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42950862 ↗
    + 2 other changes: verification date and site details
  2. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03395197
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc
Responsible party
Sponsor
First posted
Jan 10, 2018
Start date
Dec 18, 2017
Primary completion
Oct 3, 2022
Completion
Jun 30, 2027 (estimated)
Results posted
Jan 17, 2024
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Talazoparib · Enzalutamide

Start the discussion